/
CVKD
$3.02-$0.03 (-0.98%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$9.4M
3M shares
52-week range
$2.55 – $14.64
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
3.45%
Moderate
Price (6 mo)
Loading chart…
Change$-58.78
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.3K | $0 | $0 | $0 |
| Gross profit | −$1.3K | $0 | $0 | $0 |
| Gross margin | — | — | — | — |
| R&D | $392.9K | $4.1M | $4.2M | $4.1M |
| Operating income | −$2.7M | −$7.6M | −$11.0M | −$13.5M |
| EBITDA | −$6.6M | −$8.3M | −$10.6M | −$13.2M |
| Net income | −$6.7M | −$8.4M | −$10.7M | −$13.2M |
| Net margin | — | — | — | — |
| EPS (diluted) | -8.66 | -9.63 | -8.73 | -6.64 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-5.52 | $-7.74–$-4.01 | 2 |
| 2027 | $6M | $-3.42 | $-3.91–$-2.93 | 1 |
| 2028 | $17M | $-2.61 | $-2.89–$-2.33 | 2 |
| 2029 | $0 | $8.55 | $8.55–$8.55 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.72
Price
$3.02
Implied downside
-43%
Peer comparison
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
www.cadrenal.com- Employees
- 5
- IPO / List date
- Jan 20, 2023
- HQ
- PONTE VEDRA, FL
Held by traders on TradeandTell
No one on the platform currently holds CVKD.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CVKD as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-20 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded CVKD yet.
